Ipsen is committed to providing simple lay/plain language results summaries of all our interventional clinical trials that started from January 2022 or started before January 2022 and with an end date after January 2023. The summaries aim to make clinical study information accessible to everyone. They are typically published within a year following the end of the trial or shortly after the marketing authorization has been granted.
On this page you can find summaries of clinical trials that Ipsen has sponsored and clinical trials that were acquired by Ipsen. You can use the search bar to find summaries by keyword and the drop-down list to find summaries by condition(s).
The summaries provided here serve informational purposes and are not intended for promotional use. They do not constitute any form of endorsement, recommendation, or solicitation. Instead, they fulfill regulatory requirements and reflect our commitment to transparency regarding clinical trials.
Filter
Condition
Period
Filter by
recent search
Showing: 1 – 05 of 9 Conditions
–
08 November 2024
08 November 2024
LinkedIn
Twitter
Facebook
Lipisomal irinotecan compared to standard treatment
Lipisomal irinotecan compared to standard treatment in people whose lung cancer worsened after initial treatment
LinkedIn
 in patients with advanced cancer&media=https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2024/08/26173609/Image1.png "Share on LinkedIn")
LinkedIn
–
09 August 2024
09 August 2024
LinkedIn
–
09 August 2024
09 August 2024
LinkedIn
–
09 August 2024
09 August 2024
LinkedIn
–
09 August 2024
09 August 2024
LinkedIn
A study on the effectiveness of the treatment for patients with non-functioning neuroendocrine tumours of the pancreas, intestines or unknown origin.
Somatuline autogel (lanreotide autogel)
–
09 August 2024
09 August 2024
LinkedIn
–
05 May 2023
05 May 2023
&media=https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2024/08/26173609/Image1.png "Share on LinkedIn")
LinkedIn
Contact
-
Product & medical information
-
